Wham! Alexion investors sucker-punched as PTO takes up Amgen’s Soliris patent challenge
Alexion Pharmaceuticals investors were celebrating last week when word on the street said Amgen might buy out the company, but a week later, their mood is much different. The buyout hope was dashed Monday when Amgen announced it would buy Celgene’s Otezla, and now the U.S. Patent and Trademark Office (PTO) has struck up a review of… Read More »